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The Zika virus (ZIKV) belongs to the Flaviviridae family and it’s transmitted mainly by mosquitoes of the
Aedes genera. The virus has a +ssRNA genome with a single ORF encapsulated in an icosahedral capside
and surroundedby a lipid membrane [Fig.1].
The most recent outbreak was in Brazil in 2015, when it was first discovered the association of ZIKV
infection with severe complications and vertical and sexual transmission.
OBJECTIVE: The aim of this study is to review the new vaccine candidates that are being researched and tested at the
moment, with main focus on the ones that progressed to clinical trials, and conclude which ones would fit best each
situation.
METHODOLOGY: All the information for this project was extracted from scientific articles and reviews, WHO reports and
reliablewebpages. All graphics are elaborated with Microsoft Power Point.
Figure 1 – ZIKV genomeorganisation and structure
(A) Negative-sensed single stranded RNA genome of 10.8kb in length.
The capsid (C), premembrane (prM) and envelope (E) genes are
structural. The genome also encodes for seven non-structural genes
(NS1-NS5). (B) Virion structure of the ZIKV. RNA (red) inside the capside
(yellow), and lipid membrane (orange) with E (green) and M (blue)
proteins.
Figure 2 – Construction of a DNA vaccine against ZIKV
Construction of a DNA vaccine from a West Nile Virus vaccine backbone. The main coding sequence of the WNV vaccine is
enzymatically deleted and substituted by the prM and E proteins from wild type ZIKV.
Figure 3 – Construction of a live-attenuated vaccine against ZIKV
Steps for the construction of a LAV from a mutant 3’UTR library of wild type ZIKV. Clones with different deletions are generated
and then cultured in a Vero cell line. Later on, they are harvested, selected, and administered to mice.
Figure 4 – Construction of a purified inactivated vaccine against ZIKV
Steps for the construction of a PIV. First viruses are cultured and harvested, then purified and later on inactivated by
formalin treatment. The combination with the inactivated virus with an adjuvant, in this case aluminium hydroxide,
constitutes the vaccine.
Figure 5 – Construction of a mRNA modified vaccine against ZIKV
Steps for the construction of a prM-E mRNA-LNP vaccine. The mRNA is modified to the desired construction and
encapsulated in a self-assembly process by mixing the modified mRNA solution with an ethanol solution containing the
LNPs constituting lipids.
PROS:
o DNA	is	stable	
o Stablished	manufacturing	process
o Elicit	antibody	and	cellular	response
CONS:	
o Loss	of	immunity	overtime.	
o Could	lead	to	integration	in	chromosomes	
(insertional	mutagenesis)
PROS:
o Single	dose	
o Long-lived	protection
o Rapid	and	robust	immune	response
o Protect	against	vertical	transmission
CONS:	
o Need	to	be	kept	in	cool
o Contraindicated	for	immunocompromised	
patients	and	pregnant	women.		
PROS:
o Good safety profile
o Effectiveness demonstrated with JEV
o Optimised manufacture (cDNA clone)
CONS:	
o Immunity	is	not	as	strong	as	live	vaccines
o Require	more	than	one	dose	or	booster	
shots
PROS:
o Single	low	doses
o Very	versatile	and	cost-effective
o High-safety	profile		
o Protect	against	vertical	transmission
CONS:	
o mRNA	is	not	as	stable	as	DNA
It consists of prM and E genes encoded under the control of a promoter. mRNA vaccine
is delivered via optimised lipid nanoparticles (LNPs) [Fig.5]. mRNA translates directly
intro a protein in the cytoplasm, so it bypasses the nuclear step. Sub-viral particles
assemble and mimic the ZIKV usual cycle and trigger a rapid and potent immune
response. They overcome the safety risks associated with live virus vaccines.
They use an attenuated form of ZIKV, alive but with reduced virulence. Attenuation is
achieved by deletions in the 3’UTR, which slows down ZIKV genome replication [Fig.3].
Moreover, mutant 3’UTR viruses are more sensitive to interferon-ß inhibition. They
generate E-protein-expressing infectious non-virulent viruses that will trigger a long
lasting immune response.
It consists in plasmids encoding prM and E genes under the control of a promoter
[Fig.2]. In this case, WNV vaccine was used as the backbone, since there was evidence
that the vaccine was immunogenic and safe. When the proteins express in mammalian
cells, they assemble into subviral particles, non-infectious but immunogenic, and trigger
an immune response.
They contain the killed ZIKV. The virus follows a process of purification and inactivation
to obtain non-infectious and non-virulent subviral particles that will be administered as
a vaccine [Fig.4]. The inactivated viruses are easily administered, elicit robust
neutralising antibody titers and have no significant adverse effects. PIV have been
licensed against JEV and TBE, therefore ZPIV remains a promising candidate.
The main reason for the need of a vaccine is to avoid vertical transmission and the associated neurological disorders. Therefore, the main target population should be women who are
pregnant or at a reproductive age. Due to that, safety requirements are unique. It has to be taken into account that there’s a lack of epidemiological data and studies about the
infection, disease and complications. Hence, different vaccine platforms should be developed to target different situations.
All of the newest vaccine candidates elicit high titers of neutralising antibodies that protect against ZIKV challenge, viremia and tissue viral burden; however, mRNA-LNPs vaccines
might be the best option for at-risk populations, since they protect against vertical transmission, are safe and immunogenic. Although more time is needed to see if the conferred
protection is sustained overtime, it seems that we are on the right path for de development of an effective vaccine against ZIKV.
